These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 12582457

  • 1. The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases.
    Ricart E, Bouma G, Peña AS.
    Drugs Today (Barc); 2002 Nov; 38(11):725-44. PubMed ID: 12582457
    [Abstract] [Full Text] [Related]

  • 2. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P, Van Assche G, Vermeire S.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):451-63. PubMed ID: 16441465
    [Abstract] [Full Text] [Related]

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 4. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB.
    Gut; 2007 Sep 14; 56(9):1181-3. PubMed ID: 17698862
    [Abstract] [Full Text] [Related]

  • 5. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.
    Gastroenterology; 2015 Jun 14; 148(7):1320-9.e3. PubMed ID: 25724455
    [Abstract] [Full Text] [Related]

  • 6. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
    Marits P, Landucci L, Sundin U, Davidsdottir L, Nilsson J, Befrits R, Wikström AC, Eberhardson M.
    J Crohns Colitis; 2014 Aug 14; 8(8):881-9. PubMed ID: 24486178
    [Abstract] [Full Text] [Related]

  • 7. A review of infliximab use in ulcerative colitis.
    Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.
    Clin Ther; 2008 Feb 14; 30(2):223-30. PubMed ID: 18343261
    [Abstract] [Full Text] [Related]

  • 8. Infliximab treatment for Crohn's disease.
    Conroy CA, Cattell R.
    Postgrad Med J; 2001 Jul 14; 77(909):436-40. PubMed ID: 11423591
    [No Abstract] [Full Text] [Related]

  • 9. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ.
    Expert Rev Gastroenterol Hepatol; 2015 Jul 14; 9 Suppl 1():35-44. PubMed ID: 26395533
    [Abstract] [Full Text] [Related]

  • 10. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun 14; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 11. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P.
    Expert Rev Gastroenterol Hepatol; 2015 Jun 14; 9 Suppl 1():45-52. PubMed ID: 26395534
    [Abstract] [Full Text] [Related]

  • 12. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease.
    Bell S, Kamm MA.
    Lancet; 2000 Mar 11; 355(9207):858-60. PubMed ID: 10752696
    [No Abstract] [Full Text] [Related]

  • 13. New strategies in the management of inflammatory bowel disease.
    Rutgeerts P, Baert F.
    Acta Clin Belg; 1999 Oct 11; 54(5):274-80. PubMed ID: 10555385
    [Abstract] [Full Text] [Related]

  • 14. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG, Enns R, Fedorak RN, Panaccione R, Paré P, Steinhart AH, Wild G.
    Can J Clin Pharmacol; 2001 Oct 11; 8(4):188-98. PubMed ID: 11743591
    [Abstract] [Full Text] [Related]

  • 15. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.
    Koelewijn C, Schrijvers A, Oldenburg B.
    Neth J Med; 2006 Oct 11; 64(7):212-8. PubMed ID: 16929082
    [No Abstract] [Full Text] [Related]

  • 16. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.
    Sofia MA, Rubin DT.
    Dig Dis Sci; 2017 Apr 11; 62(4):833-842. PubMed ID: 28197743
    [Abstract] [Full Text] [Related]

  • 17. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
    Seiderer J, Göke B, Ochsenkühn T.
    Digestion; 2004 Apr 11; 70(1):3-9. PubMed ID: 15297773
    [Abstract] [Full Text] [Related]

  • 18. Is infliximab effective for induction of remission in patients with ulcerative colitis?
    Lichtenstein GR.
    Inflamm Bowel Dis; 2001 May 11; 7(2):89-93. PubMed ID: 11383596
    [No Abstract] [Full Text] [Related]

  • 19. The cost-effectiveness of infliximab in Crohn's disease.
    Smart C, Selinger CP.
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct 11; 14(5):589-98. PubMed ID: 25138162
    [Abstract] [Full Text] [Related]

  • 20. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Aug 01; 20(3):303-10. PubMed ID: 15274667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.